Seeking Clues to Medtronic (MDT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.20 per share, unchanged from the same period last year, with revenues forecasted at $7.9 billion, reflecting a year-over-year increase of 2.5% [1] - The consensus EPS estimate has remained stable over the past 30 days, indicating analysts' reassessment of their projections [1] Revenue Estimates - Analysts predict 'Net Sales- World Wide Revenue- Cardiovascular' to be $2.92 billion, a year-over-year increase of 2.6% [2] - 'Net Sales- World Wide Revenue- Diabetes' is expected to reach $613.04 million, indicating a 6.1% increase year over year [2] - 'Net Sales- World Wide Revenue- Medical Surgical' is estimated at $2.06 billion, reflecting a 1.1% year-over-year change [2] Additional Revenue Projections - 'Net Sales- World Wide Revenue- Neuroscience' is projected at $2.29 billion, showing a 3.3% increase from the prior-year quarter [3] - 'Net Sales- U.S. Revenue' is expected to be $4.03 billion, indicating a 2.6% change from the year-ago quarter [3] - 'Net Sales- ROW- Cardiovascular- Structural Heart & Aortic' is forecasted at $480.82 million, reflecting a 5.2% increase year over year [3] Regional and Segment Revenue Insights - 'Net Sales- ROW- Cardiovascular' is projected to reach $1.55 billion, indicating a year-over-year change of 3.6% [4] - 'Net Sales- U.S. Revenue- Cardiovascular- Cardiac Rhythm & Heart Failure' is estimated at $734.17 million, reflecting a 2% change from the prior-year quarter [4] - 'Net Sales- U.S. Revenue- Cardiovascular' is expected to be $1.37 billion, indicating a 1.5% increase from the year-ago quarter [4] Stock Performance - Over the past month, Medtronic shares have returned +0.6%, while the Zacks S&P 500 composite has decreased by -2.9% [4] - Medtronic currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [4]